B-Cell Receptor Signaling in Diffuse Large B-Cell lymphoma

摘要: The importance of understanding the genetic and biochemical basis B-cell receptor (BCR) survival signaling in diffuse large lymphoma (DLBCL) is underscored by recent clinical success agents that target BCR pathway. DLBCL composed multiple distinct molecular subtypes with divergent outcomes. activated B-cell-like (ABC) subtype most aggressive form often resistant to standard chemotherapies. ABC expresses numerous genes found antigen-activated B cells, pharmacologic studies have demonstrated tumors are addicted NF-κB activity. origins this activity remained obscure until RNA interference screens established majority cell lines rely on expression components downstream effectors for activation. Pharmacological inhibition ibrutinib Bruton's tyrosine kinase, a kinase required engage NF-κB, selectively toxic tumors; finding has now been translated clinic. These novel targets not only offer promising new therapy option DLBCL, but also demonstrate value deep oncogenic pathways.